Histogenics Corporation, a clinical-stage company, focuses on the development of restorative cell therapies in the United States. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. It has an exclusive channel collaboration agreement with Intrexon Corporation for the development and commercialization of allogeneic genetically modified chondrocyte cell therapeutics for the treatment or repair of damaged articular hyaline cartilage in humans. Histogenics Corporation was founded in 2000 and is headquartered in Waltham, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:HSGX
Previous Symbol
CUSIPN/A
Phone781-547-7900
Debt
Debt-to-Equity RatioN/A
Current Ratio0.67
Quick Ratio0.67
Price-To-Earnings
Trailing P/E Ratio-0.46
Forward P/E Ratio-2.03
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value($0.33) per share
Price / Book-1.35
Profitability
EPS (Most Recent Fiscal Year)($0.98)
Net Income$-26,410,000.00
Net MarginsN/A
Return on EquityN/A
Return on Assets-60.55%
Miscellaneous
Employees45
Outstanding Shares29,240,000
Market Cap$12.86 million
OptionableNot Optionable
Histogenics (NASDAQ:HSGX) Frequently Asked Questions
What is Histogenics' stock symbol?
Histogenics trades on the NASDAQ under the ticker symbol "HSGX."
How were Histogenics' earnings last quarter?
Histogenics Corp (NASDAQ:HSGX) posted its quarterly earnings data on Thursday, November, 8th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by $0.05. View Histogenics' Earnings History.
When is Histogenics' next earnings date?
What price target have analysts set for HSGX?
5 equities research analysts have issued 12 month target prices for Histogenics' stock. Their predictions range from $1.00 to $5.00. On average, they anticipate Histogenics' share price to reach $3.3750 in the next twelve months. This suggests a possible upside of 650.0% from the stock's current price. View Analyst Price Targets for Histogenics.
What is the consensus analysts' recommendation for Histogenics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Histogenics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Histogenics.
What are Wall Street analysts saying about Histogenics stock?
Here are some recent quotes from research analysts about Histogenics stock:
- 1. According to Zacks Investment Research, "Histogenics Corporation is a regenerative medicine company. It is focused on developing and commercializing products in the musculoskeletal segment. The company is developing NeoCart(R) product to provide treatment in the orthopedic space. Histogenics Corporation is headquartered in Waltham, Massachusetts. " (11/13/2018)
- 2. HC Wainwright analysts commented, "We maintain our Buy rating of HSGX and lower our 12-month price target to $2.00 per share, down from $3.50. We derive our price target based on a risk-adjusted net present value analysis of projected NeoCart revenues until 2027 assuming a 12% discount rate and a 3% terminal value. We derive an rNPV of $97M for NeoCart and add $9M in cash and cash equivalents to arrive at a 12-month price target of $1.99 per diluted share, which we round to $2.00. (1) clinical; (2) commercial; (3) partnership; (4) financial; and (5) legal and intellectual property." (9/5/2018)
Has Histogenics been receiving favorable news coverage?
Media coverage about HSGX stock has trended positive this week, InfoTrie reports. The research firm ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Histogenics earned a media sentiment score of 2.3 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the near future.
Are investors shorting Histogenics?
Histogenics saw a increase in short interest during the month of October. As of October 31st, there was short interest totalling 4,746,237 shares, an increase of 204.3% from the October 15th total of 1,559,679 shares. Based on an average trading volume of 9,592,913 shares, the days-to-cover ratio is presently 0.5 days. Currently, 31.6% of the shares of the stock are short sold. View Histogenics' Current Options Chain.
Who are some of Histogenics' key competitors?
Who are Histogenics' key executives?
Histogenics' management team includes the folowing people:
- Mr. Adam D. Gridley, Pres, CEO & Director (Age 46)
- Mr. Jonathan I. Lieber, Chief Financial Officer (Age 48)
- Mr. Stephen R. Kennedy, Exec. VP & COO (Age 61)
- Dr. Donald D. Haut, Chief Bus. Officer (Age 52)
- Dr. E. Lynne Kelley M.D., FACS, Chief Medical Officer (Age 55)
When did Histogenics IPO?
(HSGX) raised $60 million in an initial public offering (IPO) on Wednesday, December 3rd 2014. The company issued 4,300,000 shares at a price of $13.00-$15.00 per share. Cowen and Company, Needham & Company and Canaccord Genuity served as the underwriters for the IPO and BTIG was co-manager.
Who are Histogenics' major shareholders?
Histogenics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Perceptive Advisors LLC (4.12%) and Virtu Financial LLC (0.73%). Company insiders that own Histogenics stock include Adam Gridley, David N Gill and Jonathan I Lieber. View Institutional Ownership Trends for Histogenics.
Which major investors are selling Histogenics stock?
Which major investors are buying Histogenics stock?
HSGX stock was bought by a variety of institutional investors in the last quarter, including Virtu Financial LLC. Company insiders that have bought Histogenics stock in the last two years include Adam Gridley, David N Gill and Jonathan I Lieber. View Insider Buying and Selling for Histogenics.
How do I buy shares of Histogenics?
Shares of HSGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Histogenics' stock price today?
One share of HSGX stock can currently be purchased for approximately $0.45.
How big of a company is Histogenics?
Histogenics has a market capitalization of $12.86 million. The biotechnology company earns $-26,410,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. Histogenics employs 45 workers across the globe.
What is Histogenics' official website?
How can I contact Histogenics?
Histogenics' mailing address is 830 WINTER STREET 3RD FLOOR, WALTHAM MA, 02451. The biotechnology company can be reached via phone at 781-547-7900 or via email at [email protected]
MarketBeat Community Rating for Histogenics (NASDAQ HSGX)
MarketBeat's community ratings are surveys of what our community members think about Histogenics and other stocks. Vote "Outperform" if you believe HSGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HSGX will underperform the S&P 500 over the long term. You may vote once every thirty days.
